Patrick K. Lucy
Independent ChairmanMr. Patrick K. Lucy is President, CEO & Director of Wheeler Bio, Inc. He is also Chief Executive Officer of Wheeler Bio, Inc. from October, 2024. Mr. Lucy serves as Independent Chairman at Dyadic International, Inc. since March 28, 2024. He has extensive experience in the biotechnology industry. As a seasoned senior executive, he has overseen numerous company milestones and driven significant growth. He served as President and CEO of RoslinCT US. Under his leadership, he led the successful launch of the Lykan business he orchestrated its sale to GHO Capital, providing a successful exit for the original private equity investors. He serves as President and Chief Executive Officer at Lykan since April 1, 2021. He was the President and Chief Operating Officer of Lykan Bioscience a privately held cell therapy contract manufacturing organization based in Hopkinton, Massachusetts and Edinburgh, Scotland from January 4, 2021 until March 31, 2021. He served as the Senior Vice President and Chief Business Officer of Pfenex Inc. since 2014. He was a member of the leadership team and led the commercial launch of the Pfenex platform in 2005 through the spin out of the business from Dow in 2009. Mr. Lucy was subsequently a member of the team that successfully completed Pfenex’s initial public offering in 2014 and continued to lead business/corporate development and portfolio strategy as Chief Business Officer. He serves as an Additional Independent Director at Dyadic International, Inc. since January 8, 2021. Mr. Lucy served as Interim Chief Executive Officer, President and Secretary at Pfenex Inc. from January 24, 2017 to August 2017 and previously served as its Vice President of Business Development and Marketing between 2009 and 2014. He serves on the Scientific Advisory Board of immuTide, Inc. He played a leadership role on the original team that developed Pfenex Expression Technology™ and subsequently led the successful commercial launch of the platform in 2004. He has led the negotiation and completion of numerous technology partnering, licensing, manufacturing and collaboration agreements with the federal government and pharmaceutical companies worldwide. Mr. Lucy held the position of Director of Business Development at DowPharma from 2002 to 2009. From 1999 to 2002, he held the position of Director of Business Development at Collaborative BioAlliance, Inc. From 1998 to 1999, Mr. Lucy worked as a Validation Manager and Capital Project Manager and from 1996 to 1998, as a Quality Control Biochemistry Supervisor at Lonza Biologics Inc. From 1991 to 1996, Mr. Lucy held various positions at Repligen Corporation. Mr. Lucy co-founded Pfenex Inc. a publicly traded biotechnology company that started as a spin-out from The Dow Chemical Company in 2009 and was later acquired by Ligand Pharmaceuticals in October 2020. Mr. Lucy is experienced in the areas of alliance management, licensing, intellectual property, biopharmaceutical operations and biopharmaceutical facility design, construction and validation. Prior to his role in Pfenex, Mr. Lucy was employed by The Dow Chemical Company for nine years in business development roles for the Dowpharma business unit. Prior to joining Dow in 2000, via Dow’s acquisition of Collaborative BioAlliance, he served as Collaborative’s Director of Business Development. Mr. Lucy has been in the biotechnology industry for many years and was previously employed by Collaborative BioAlliance, Inc. Lonza Biologics, Celltech Biologics and Repligen Corporation. From 1995 to 1999, he held multiple operational roles at Lonza Biologics (“Lonza”) spanning quality control, validation and capital project management. In his final role at Lonza, he led the mechanical completion, start up and validation of a large-scale biologics manufacturing facility. He served as Director of Association for Accessible Medicines. Mr. Lucy holds a BS in Biology from Villanova University.
Positions
- Company NameDyadic International, Inc.Stock CodeDYAIPositionIndependent ChairmanColleagues
